At the recent ASCO Annual Meeting in Chicago from May 30thto June 3rd, 2025, DPM demonstrated its ultra-sensitive fluorescence molecular imaging technology once again to the global oncology community, reinforcing its presence at the world's most influential cancer conference.
DPM has achieved an unprecedented milestone by becoming the first Chinese advanced surgical solution provider to present at three of the world's most prestigious medical conferences within nine months: the American Society of Clinical Oncology (ASCO) Annual Meeting, the American College of Surgeons (ACS) Clinical Congress, and the American Association for Thoracic Surgery (AATS) Annual Meeting. These conferences collectively attract over 60,000 medical professionals from more than 100 countries annually.
Such international recognition reflects DPM's commitment to competing at the highest levels of medical technology innovation. The company's consistent presence at these prestigious conferences demonstrates not just technical capability, but the confidence to engage with global medical leaders on equal footing.
With the core team originating from the Key Laboratory of Molecular Imaging at the Institute of Automation, Chinese Academy of Sciences, we brought world-class research credentials and a proven track record of translating advanced scientific discoveries into clinical solutions. These "State-of-the-Art National Technologies" has enabled the company to develop ultra-sensitive fluorescence molecular imaging technology that addresses real surgical challenges.
Our technology has been successfully implemented across 14 surgical specialties, extending far beyond traditional tumor boundary identification. In collaboration with leading surgical teams, DPM has pioneered innovative applications including precision tissue preservation, lung cancer detection and AI-powered diagnostics. These breakthrough applications have been published in top-tier international journals, establishing significant academic impact and driving the evolution of molecular imaging technology.
Looking ahead, DPM is accelerating our international expansion strategy, seeking strategic partnerships with leading global medical institutions to evolve from international recognition to global leadership. We have also been investing heavily in R&D to integrate AI and big data analytics with intraoperative molecular imaging, developing next-generation more intelligent and personalized surgical solutions for patients worldwide.
